A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies
WCLC 2019 Review – Part 3 - Targeted Therapy Highlights excluding KRASi
Summary of IO highlights and lowlights from WCLC 2019
Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials
After the WCLC2018 preview, what does the data actually teach us? A round up and commentary on 16 key trials
What to watch out for at WCLC2018 in Toronto later this month
